Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
Q1 2026 revenue beat, raised revenue guidance, and the first sixth-generation 256-qubit system sale. The proof gate is RPO conversion, organic revenue growth, and adjusted EBITDA loss discipline.
OpenRevvity is trying to prove the post-spin model can protect margins while faster life-science competitors chase growth.
OpenRigetti has technical credibility and a proposed $100M federal quantum award, but the investment case still hinges on revenue scale, cash burn, fidelity, and system roadmap execution.
OpenSoFi is growing across lending, financial services, and technology, but credit risk decides how durable the growth is.
OpenAI-server demand is large, but the liquidity story is about cash, working capital, and volatility.
OpenAI chips still need to be tested, and Teradyne sits in that less flashy bottleneck.
OpenPfizer reported FY2025 revenue of $62.6 billion and Q1 2026 revenue of $14.5 billion. The thesis depends on portfolio durability, oncology integration, patent cliffs, operating cash flow, debt capacity and pipeline execution.
OpenJoby needs certification progress to arrive before liquidity concerns dominate the air-taxi story.
OpenJoby has an ambitious air-taxi network vision, but the financial runway comes before scale.
OpenIonQ needs to prove its quantum advantage can survive competition from larger tech platforms with deeper budgets.
OpenIonQ benefits from quantum-computing excitement, but investors need to separate scientific progress from commercial revenue.
OpenInfleqtion has a clean quantum identity, record Q1 revenue, and a proposed $100M federal tailwind, but the business still needs revenue scale and operating-loss discipline.
OpenHims & Hers expanded its subscriber benefits bundle to ten partner brands. The update is not a direct revenue story yet; it is a retention, churn, and marketing-efficiency proof test.
OpenHIMS Q1 met the revenue test and raised revenue guidance, but lower margins and reduced adjusted EBITDA guidance keep the thesis conditional.
OpenHims is using GLP-1 weight loss to expand the platform, but the quality test is retention and cash flow.
OpenHims & Hers opened a Canada generic semaglutide path and closed $402.5M of zero-coupon convertible debt. The update turns HIMS into a global expansion versus dilution proof test.
OpenEnphase reported Q1 2026 results and announced an IQ solid-state transformer program for AI data centers. The proof gate is revenue stabilization, battery shipments, non-GAAP gross margin, and IQ SST progress.
OpenEnphase has strong technology, but residential solar demand is sensitive to financing costs.
OpenGinkgo has moved from broad synthetic-biology promise toward a harder profitability test.
OpenBitMine priced an upsized preferred-stock deal, and the real question is whether ETH treasury growth can beat a new preferred dividend claim that sits ahead of common shareholders.
Open